Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
PADCEV (Astellas Pharma Australia Pty Ltd)
Product name
PADCEV
Date registered
Evaluation commenced
Decision date
Approval time
240 (255 working days)
Active ingredients
enfortumab vedotin
Registration type
NCE/NBE
Indication
PADCEV as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand-1 inhibitor.